ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
MHRA authorises Lilly’s RET inhibitor Retsevmo pharmatimes
March 11, 2021The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Eli Lilly’s Retsevmo a conditional marketing authorisation for the treatment of RET fusion-positive advanced lung cancer and thyroid cancer.
Pharma Sources Insight January 2025
